Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
First Claim
1. A pharmaceutical composition in the form of mixed micelles, comprising:
- a calcineurin inhibitor or a mammalian target of rapamycin (mTOR) inhibitor;
vitamin E tocopherol polyethylene glycol succinate (TPGS) with a hydrophilic/lipophilic balance (HLB) index greater than about 10; and
octoxynol-40 with an HLB index of greater than about 13,wherein an absolute difference between the HLB index of the vitamin E TPGS and the HLB index of the octoxynol-40 is greater than about 3, andwherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40.
2 Assignments
0 Petitions
Accused Products
Abstract
The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.
213 Citations
49 Claims
-
1. A pharmaceutical composition in the form of mixed micelles, comprising:
-
a calcineurin inhibitor or a mammalian target of rapamycin (mTOR) inhibitor; vitamin E tocopherol polyethylene glycol succinate (TPGS) with a hydrophilic/lipophilic balance (HLB) index greater than about 10; and octoxynol-40 with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the vitamin E TPGS and the HLB index of the octoxynol-40 is greater than about 3, and wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40. - View Dependent Claims (2, 40, 41, 42, 43)
-
-
3. A pharmaceutical composition in the form of mixed micelles, comprising:
-
a calcineurin inhibitor; vitamin E tocopherol polyethylene glycol succinate (TPGS); and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40 and is suitable for topical application to ocular tissue. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 44)
-
-
12. A pharmaceutical composition in the form of mixed micelles, comprising:
-
a mammalian target of rapamycin (mTOR) inhibitor; vitamin E tocopherol polyethylene glycol succinate (TPGS); and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40 and is suitable for topical application to ocular tissue. - View Dependent Claims (13, 14, 45)
-
- 15. An artificial tear composition comprising an aqueous solution of mixed micelles, the mixed micelles formed from vitamin E tocopherol polyethylene glycol succinate (TPGS) and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40.
-
19. A pharmaceutical composition in the form of mixed micelles, comprising:
-
voclosporin; vitamin E tocopherol polyethylene glycol succinate (TPGS); and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40 and is suitable for topical application to ocular tissue. - View Dependent Claims (20, 21, 22, 23, 24, 46)
-
-
25. A pharmaceutical composition in the form of mixed micelles, comprising:
-
cyclosporine A; vitamin E tocopherol polyethylene glycol succinate (TPGS); and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40 and is suitable for topical application to ocular tissue. - View Dependent Claims (26, 27, 28, 29, 47)
-
-
30. A pharmaceutical composition in the form of mixed micelles, comprising:
-
tacrolimus; vitamin E tocopherol polyethylene glycol succinate (TPGS); and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40 and is suitable for topical application to ocular tissue. - View Dependent Claims (31, 32, 33, 34, 48)
-
-
35. A pharmaceutical composition in the form of mixed micelles, comprising:
-
sirolimus; vitamin E tocopherol polyethylene glycol succinate (TPGS); and octoxynol-40, wherein the composition is in the form of mixed micelles having the vitamin E TPGS and the octoxynol-40 and is suitable for topical application to ocular tissue. - View Dependent Claims (36, 37, 38, 39, 49)
-
Specification